TargeGen successfully completed enrollment of a multi-center clinical trial of TG101348

UCSD, TargeGen team-up on blood disease treatment

A one-year scientific collaboration that included the University of California San Diego and the tiny local biotechnology company TargeGen has moved a treatment for a potentially fatal blood disease into human trials at record speed.

TargeGen initiates Phase I clinical trial of topical AMD drug TG100801

TargeGen, Inc. has announced that the Company has initiated a single site Phase I clinical trial involving TG100801, a small molecule, topically applied multi-targeted kinase inhibitor for the treatment of macular degeneration and other debilitating diseases of the eye. Macular degeneration is the leading cause of blindness in adults. The trial, involving approximately 45 subjects, is expected to be completed by the end of the first quarter of 2007. The Company hopes to initiate Phase II studies with TG100801 in mid 2007.

TargeGen, Inc. Selects Lead Drug for Clinical Development As A Topical (Eyedrop) Treatment For Wet Macular Degeneration and Other Eye Diseases

TargeGen, Inc., a biopharmaceutical company focusing on the development of small molecule drugs for the treatment of edema and angiogenesis related diseases, today announced that TG 100801, a potent, selective, and topically administered multi target kinase inhibitor, has been designated as a lead drug for clinical development in the treatment of major eye diseases including macular degeneration, diabetic macular edema and diabetic retinopathy. Current treatments for wet macular degeneration have demonstrated limited efficacy to date and require injection into the eye, thus increasing the risk of infection and retinal detachment.